When looking through the ‘treatment zones’ of three different types of myopia controlling spectacle lenses with lenslets, visual acuity is reduced by 3-5 letters and mid-to-high frequency contrast sensitivity is mildly affected compared to single vision spectacles. We’re yet to learn if small differences between designs may influence patient preference.
Children who had already participated in the two-year clinical trial either continued wearing DIMS or switched from the control SV to DIMS. Comparison to an age-matched historical control group showed a myopia control effect in the third year.
This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.
This study reports one year results from an ongoing randomized clinical trial examining spectacle lenses with highly aspherical lenslet (HAL) or slightly aspherical lenslet (SAL) technology. The findings showed the HAL lens controlled refractive and axial progression by 60-70% and SAL by 30-40% over the first 12 months.
This randomised trial demonstrated MiSight 1 day gives a quality of vision similar to a single vision lens for the wearer and can be dispensed according to non-cycloplegic refraction.
This study evaluates how orthok treatment zone diameter influences change in refraction and axial eye length over 1-year in children previously fit with orthok lenses of varying back optic zone diameter, to reveal that where treatment zone diameter was less than pupil diameter orthok’s myopia control efficacy appeared to be improved.
The purpose of this 2 year study was to determine the effect of MiSight contact lenses used to control myopia on binocular vision and accommodation in children, as compared with children wearing SV spectacles, with the researches finding no significant differences in binocular and accommodative measures between the study groups.
Despite being used for myopia management for many years, significant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine. The LAMP study sheds light on this mystery by investigating efficacy of 0.05%, 0.025% and 0.01% atropine for slowing myopia progression.
In this review we explore the 6-year results for MiSight 1 day recently presented at the 2020 American Academy of Optometry meeting. Based on the abstract, children who were older at initial fitting (11-15 years) progressed similarly over 3 years to matched children who were treated for 6 years, indicating that older children could still gain a treatment effect from MiSight 1 day.
Can body height compared to axial length be used to predict risk of myopia or high myopia? This longitudinal study examined body height, axial length and refraction – growth mechanisms are likely linked in emmetropes but not in myopes.
